Wells Fargo’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$79K Sell
24,923
-19,160
-43% -$69.7K ﹤0.01% 5270
2026
Q2
$172K Buy
+44,083
New +$164K ﹤0.01% 5285
2024
Q2
– Sell
-61
Closed -$277 – 7382
2024
Q1
$277 Buy
61
+32
+110% +$176 ﹤0.01% 6419
2023
Q4
$202 Buy
29
+2
+7% +$17 ﹤0.01% 6610
2023
Q3
$169 Buy
27
+2
+8% +$15 ﹤0.01% 6628
2023
Q2
$205 Buy
25
+6
+32% +$49 ﹤0.01% 6694
2023
Q1
$82 Hold
19
– – ﹤0.01% 6979
2022
Q4
$109 Buy
19
+1
+6% +$9 ﹤0.01% 6771
2022
Q3
$0 Buy
18
+1
+6% +$10 ﹤0.01% 7255
2022
Q2
$0 Buy
+17
New +$357 ﹤0.01% 7384

Other funds holding SABS

Wells Fargo's SABS Position: Q3 2026 in Review

Wells Fargo reduced its SAB Biotherapeutics (SABS) stake by 43% in Q3 2026, selling an estimated $69.7K and leaving 24,923 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #5270.

Wells Fargo first reported a position in SABS in Q2 2022 and has held it in 10 quarters since. The position peaked at $172K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Wells Fargo held 24,923 shares of SAB Biotherapeutics worth $79K as of Q3 2026.
  • Wells Fargo sold 19,160 SAB Biotherapeutics shares in Q3 2026, an estimated $69.7K.
  • SAB Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5270 holding.
  • Wells Fargo first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 10 quarters since.
  • Wells Fargo's SAB Biotherapeutics position peaked at $172K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.